Chào mừng trở lại
Bấm vào "Đăng nhập " để đồng ý Điều khoản dịch vụ Cointime và xác nhận rằng Chính sách bảo mật Cointime là dành cho bạn.
Tham gia Cointime
Đã có tài khoản?
Bấm vào "Đăng nhập " để đồng ý Điều khoản dịch vụ Cointime và xác nhận rằng Chính sách bảo mật Cointime là dành cho bạn.
Đăng nhập với email
Đăng nhập với
Email của bạn
Đăng ký
Bấm vào liên kết chúng tôi gửi tới để đăng nhập
Nhấp vào liên kết chúng tôi đã gửi tới để đăng ký.
SparingVision
company
About
SparingVision is a biotechnology company developing genomic medicines for the treatment of blinding inherited retinal diseases.
- 11 - 50
Details
- Last Funding Type
- Corporate Round
- Industries
- Biotechnology,Health Care,Life Science
- Founded date
- Jan 1, 2016
- Number Of Employee
- 11 - 50
- Operating Status
- Active
SparingVision is a biotechnology company focused on the discovery and development of innovative therapies for the treatment of blinding inherited retinal diseases. SparingVision is developing SPVN06, a gene-independent treatment for retinitis pigmentosa, the most common inherited retinal degeneration. There is currently no treatment to treat all genetic forms of this rare retinal disease that leads to blindness and affects nearly 2 million people worldwide.
Funding Rounds
Number of Funding Rounds
Total Funding Amount
3
€119.50M
SparingVision has raised a total of
€119.50M
in funding over 2 rounds. Their latest funding was raised on
Sep 14, 2022 from a Series B round.
| Announced Date | Round | Money Raised | Number of Investors | Lead Investors | Post Valuation | |
|---|---|---|---|---|---|---|
| Sep 14, 2022 | Series B | €75M | 1 | — | — | Detail |
| Oct 13, 2021 | Corporate Round | — | 1 |
Intellia Therapeutics
|
— | Detail |
| Oct 21, 2020 | Series A | €44.50M | 1 | — | — | Detail |
Investors
Number of Lead Investors
Number of Investors
1
3
SparingVision is funded by 3 investors.
Intellia Therapeutics
and Retinal Degeneration Fund
are the most recent investors.
| Investor Name | Lead Investor | Funding Round |
|---|---|---|
|
Intellia Therapeutics
|
Yes | Corporate Round |
Retinal Degeneration Fund
|
— | Series B |
Foundation Fighting Blindness
|
— | Series A |
Share
Twitter
LinkedIn
Line
Facebook
Telegram
Email
Page Link
